The renal cell carcinoma market is witnessing a substantial change, largely fueled by label expansions of immune checkpoint inhibitor therapies. Combination regimens, including Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical), Keytruda (Merck & Co.) plus Inlyta (Pfizer), and Bavencio (Pfizer / Merck KGaA) plus Inlyta, are revolutionizing the treatment of advanced disease. The recent approval and uptake of the Opdivo plus Cabometyx (Exelixis / Ipsen) combination will also drive fierce competition in this setting. Multiple immune checkpoint inhibitors are also anticipated to enter the early-stage setting over the forecast period. Additionally, the anticipated entry of other agents such as bempegaldesleukin (Nektar Therapeutics) and belzutifan (Merck & Co.) will further diversify treatment options and create a highly competitive and dynamic market.
Questions Answered
What is the size of the advanced or metastatic drug-treatable renal cell carcinoma population, and how will drug-treatment rates change over time?
What is the expected market impact of recent drug approvals and label expansions of novel combinations incorporating Opdivo, Cabometyx, and Keytruda for renal cell carcinoma?
Which are the most promising emerging therapies in the late-phase pipeline, and how will they shape the future of the renal cell carcinoma?
What are the drivers and constraints in the renal cell carcinoma market, and how will the market evolve over the forecast period?
Product Description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.